Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasite gamma-aminobutyric acid (GABA)-gated chloride channels are essential inhibitory neurotransmitter receptors found in the nervous systems of helminths and arthropods (Wolstenholme, 2012, 'Anthelmintic receptor diversity and genetics'). These channels belong to the Cys-loop ligand-gated ion channel superfamily and typically function as pentameric assemblies that regulate the flow of chloride ions across neuronal and muscle membranes (Raymond and Sattelle, 2002, 'GABA receptors of insects'). In many parasites, such as nematodes, these receptors (notably the UNC-49 complex) are located at neuromuscular junctions where they mediate muscle relaxation necessary for coordinated movement (Bamber et al., 1999, 'The Caenorhabditis elegans unc-49 locus encodes multiple subunits of a heteromultimeric GABA receptor'). Because these channels differ significantly in structure and pharmacology from mammalian GABA receptors, they are highly effective targets for antiparasitic agents (Gassel et al., 2014, 'The isoxazoline fluralaner is a potent antagonist of insect and tick GABA-gated chloride channels'). Drugs like piperazine act as agonists to cause flaccid paralysis, while newer classes like isoxazolines act as potent antagonists that trigger lethal hyperexcitation (Weber and Selzer, 2016, 'Isoxazolines: A novel chemotype highly effective on ectoparasites'). The specificity of these drugs for parasite channels over host channels provides a wide therapeutic window, though resistance remains a significant concern in veterinary and agricultural settings (ffrench-Constant et al., 2000, 'Cyclodiene insecticide resistance: from phenotype to gene').
Drugs targeting these channels act as either agonists, which induce flaccid paralysis by mimicking the inhibitory neurotransmitter GABA (e.g., piperazine), or as non-competitive antagonists, which block the channel to cause over-excitation, convulsions, and death of the parasite (e.g., fipronil and isoxazolines) (Bloomquist, 2003; Gassel et al., 2014).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite gamma-aminobutyric acid-gated chloride channel (GABA-Cl).